HUE068023T2 - Fenil-2-hidroxi-acetilamino-2-metil-fenil vegyületek - Google Patents
Fenil-2-hidroxi-acetilamino-2-metil-fenil vegyületekInfo
- Publication number
- HUE068023T2 HUE068023T2 HUE21211015A HUE21211015A HUE068023T2 HU E068023 T2 HUE068023 T2 HU E068023T2 HU E21211015 A HUE21211015 A HU E21211015A HU E21211015 A HUE21211015 A HU E21211015A HU E068023 T2 HUE068023 T2 HU E068023T2
- Authority
- HU
- Hungary
- Prior art keywords
- phenyl
- acetylamino
- hydroxy
- methyl
- compounds
- Prior art date
Links
- -1 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382207 | 2017-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE068023T2 true HUE068023T2 (hu) | 2024-12-28 |
Family
ID=58606227
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE21211015A HUE068023T2 (hu) | 2017-04-18 | 2018-04-11 | Fenil-2-hidroxi-acetilamino-2-metil-fenil vegyületek |
| HUE18718570A HUE057745T2 (hu) | 2017-04-18 | 2018-04-11 | Fenil-2-hidroxi-acetilamino-2-metil-fenil vegyületek |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18718570A HUE057745T2 (hu) | 2017-04-18 | 2018-04-11 | Fenil-2-hidroxi-acetilamino-2-metil-fenil vegyületek |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11655214B2 (enExample) |
| EP (2) | EP3612519B1 (enExample) |
| JP (2) | JP7110232B2 (enExample) |
| KR (2) | KR20230129627A (enExample) |
| CN (2) | CN110831927B (enExample) |
| AU (2) | AU2018255191B2 (enExample) |
| BR (1) | BR112019021867A2 (enExample) |
| CO (1) | CO2019012767A2 (enExample) |
| CR (1) | CR20190519A (enExample) |
| CY (1) | CY1125150T1 (enExample) |
| DK (2) | DK3612519T3 (enExample) |
| ES (2) | ES2906847T3 (enExample) |
| FI (1) | FI4039675T3 (enExample) |
| HR (2) | HRP20241188T1 (enExample) |
| HU (2) | HUE068023T2 (enExample) |
| IL (2) | IL270005B (enExample) |
| LT (2) | LT3612519T (enExample) |
| MX (2) | MX389724B (enExample) |
| MY (1) | MY199442A (enExample) |
| NZ (1) | NZ758291A (enExample) |
| PH (1) | PH12019502363B1 (enExample) |
| PL (2) | PL3612519T3 (enExample) |
| PT (2) | PT3612519T (enExample) |
| RS (2) | RS65914B1 (enExample) |
| SA (1) | SA519410320B1 (enExample) |
| SG (1) | SG11201909680UA (enExample) |
| SI (2) | SI4039675T1 (enExample) |
| SM (2) | SMT202400357T1 (enExample) |
| WO (1) | WO2018194885A1 (enExample) |
| ZA (1) | ZA201906811B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201909680UA (en) * | 2017-04-18 | 2019-11-28 | Lilly Co Eli | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds |
| CN112166187B (zh) | 2018-03-26 | 2025-06-20 | 西奈山伊坎医学院 | 治疗微小残留癌的方法 |
| JP2022546410A (ja) * | 2019-08-29 | 2022-11-04 | ヒベルセル， インコーポレイテッド | Ｐｅｒｋ阻害化合物 |
| US12331054B2 (en) | 2019-08-29 | 2025-06-17 | Hibercell, Inc. | Perk inhibiting imidazolopyrazine compounds |
| KR20220066290A (ko) * | 2019-08-29 | 2022-05-24 | 히버셀, 인크. | Perk 억제 피롤로피리미딘 화합물 |
| WO2021041976A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting indolinyl compounds |
| WO2021231782A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibitors for treating viral infections |
| WO2021231788A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds to treat viral infections |
| CN113234029B (zh) * | 2021-05-25 | 2022-03-22 | 白银康寓信生物科技有限公司 | 一种2-氨基-3,5-二卤代吡嗪的合成方法 |
| WO2024206890A1 (en) * | 2023-03-30 | 2024-10-03 | Hibercell, Inc. | Crystalline forms of (r)-2-amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-methylphenyl)-n-isopropylnicotinamide and methods for using the same |
| GB202407386D0 (en) | 2024-05-24 | 2024-07-10 | Apollo Ap45 Ltd | 1H-pyrazolo(4,3-D)pyrimidine derivatives |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| EP0970084B1 (en) | 1997-03-19 | 2003-06-04 | Basf Aktiengesellschaft | Pyrrolo 2,3d]pyrimidines and their use as tyrosine kinase inhibitors |
| TW200306819A (en) * | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| JP4901102B2 (ja) | 2002-05-03 | 2012-03-21 | エクセリクシス， インク． | プロテインキナーゼモジュレーターおよびその使用方法 |
| NZ544920A (en) * | 2003-07-23 | 2009-11-27 | Bayer Healthcare Llc | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
| TW200804345A (en) * | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
| WO2007026920A2 (en) * | 2005-09-02 | 2007-03-08 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
| CA2716826C (en) | 2008-02-25 | 2017-05-09 | Prometheus Laboratories Inc. | Drug selection for breast cancer therapy using antibody-based arrays |
| US20120014911A1 (en) | 2009-01-09 | 2012-01-19 | Serge Fuchs | Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor |
| US8598156B2 (en) | 2010-03-25 | 2013-12-03 | Glaxosmithkline Llc | Chemical compounds |
| WO2014170706A1 (en) | 2013-04-15 | 2014-10-23 | Università Degli Studi Di Bari | Galloyl benzamide-based compounds as jnk modulators |
| WO2015056180A1 (en) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
| JP6493218B2 (ja) | 2013-11-08 | 2019-04-03 | 小野薬品工業株式会社 | ピロロピリミジン誘導体 |
| EP3116877A1 (en) | 2014-03-11 | 2017-01-18 | Glaxosmithkline Intellectual Property (No. 2) Limited | Chemical compounds acting as perk inhibitors |
| WO2016004254A1 (en) | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
| EA039885B1 (ru) | 2014-11-14 | 2022-03-23 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы |
| GB201508747D0 (en) | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
| KR20180048635A (ko) * | 2015-07-24 | 2018-05-10 | 블루프린트 메디신즈 코포레이션 | Kit 및 pdgfr에 관련된 장애를 치료하는데 유용한 조성물 |
| KR102327917B1 (ko) | 2016-07-07 | 2021-11-17 | 주식회사 대웅제약 | 신규한 4-아미노피라졸로[3,4-d]피리미디닐아자바이사이클로 유도체 및 이를 포함하는 약학 조성물 |
| US20190241573A1 (en) | 2016-07-20 | 2019-08-08 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
| CN106748989B (zh) | 2016-11-14 | 2020-03-17 | 西安交通大学 | 一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用 |
| EP3573608A1 (en) | 2017-01-30 | 2019-12-04 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
| SG11201909680UA (en) | 2017-04-18 | 2019-11-28 | Lilly Co Eli | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds |
| US11673891B2 (en) | 2017-11-14 | 2023-06-13 | Dana-Farber Cancer Institute, Inc. | Imidazopyrimidine compounds and uses thereof |
| EP3492454A1 (en) | 2017-11-30 | 2019-06-05 | Step Pharma S.A.S. | Compounds |
| CN112166187B (zh) | 2018-03-26 | 2025-06-20 | 西奈山伊坎医学院 | 治疗微小残留癌的方法 |
| CA3104398A1 (en) | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| EP3860578A1 (en) | 2018-10-01 | 2021-08-11 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of inhibitors of stress granule formation for targeting the regulation of immune responses |
-
2018
- 2018-04-11 SG SG11201909680U patent/SG11201909680UA/en unknown
- 2018-04-11 CN CN201880033126.5A patent/CN110831927B/zh active Active
- 2018-04-11 LT LTEPPCT/US2018/027005T patent/LT3612519T/lt unknown
- 2018-04-11 LT LTEP21211015.9T patent/LT4039675T/lt unknown
- 2018-04-11 SM SM20240357T patent/SMT202400357T1/it unknown
- 2018-04-11 PL PL18718570T patent/PL3612519T3/pl unknown
- 2018-04-11 BR BR112019021867-0A patent/BR112019021867A2/pt not_active Application Discontinuation
- 2018-04-11 RS RS20240950A patent/RS65914B1/sr unknown
- 2018-04-11 PT PT187185707T patent/PT3612519T/pt unknown
- 2018-04-11 HU HUE21211015A patent/HUE068023T2/hu unknown
- 2018-04-11 SI SI201831149T patent/SI4039675T1/sl unknown
- 2018-04-11 SI SI201830572T patent/SI3612519T1/sl unknown
- 2018-04-11 ES ES18718570T patent/ES2906847T3/es active Active
- 2018-04-11 NZ NZ758291A patent/NZ758291A/en unknown
- 2018-04-11 US US16/606,410 patent/US11655214B2/en active Active
- 2018-04-11 HU HUE18718570A patent/HUE057745T2/hu unknown
- 2018-04-11 PL PL21211015.9T patent/PL4039675T3/pl unknown
- 2018-04-11 JP JP2019556703A patent/JP7110232B2/ja active Active
- 2018-04-11 MX MX2019012428A patent/MX389724B/es unknown
- 2018-04-11 DK DK18718570.7T patent/DK3612519T3/da active
- 2018-04-11 ES ES21211015T patent/ES2988739T3/es active Active
- 2018-04-11 EP EP18718570.7A patent/EP3612519B1/en active Active
- 2018-04-11 FI FIEP21211015.9T patent/FI4039675T3/fi active
- 2018-04-11 CR CR20190519A patent/CR20190519A/es unknown
- 2018-04-11 KR KR1020237029674A patent/KR20230129627A/ko not_active Ceased
- 2018-04-11 SM SM20220100T patent/SMT202200100T1/it unknown
- 2018-04-11 HR HRP20241188TT patent/HRP20241188T1/hr unknown
- 2018-04-11 PT PT212110159T patent/PT4039675T/pt unknown
- 2018-04-11 KR KR1020197033523A patent/KR102575246B1/ko active Active
- 2018-04-11 AU AU2018255191A patent/AU2018255191B2/en active Active
- 2018-04-11 HR HRP20220263TT patent/HRP20220263T1/hr unknown
- 2018-04-11 WO PCT/US2018/027005 patent/WO2018194885A1/en not_active Ceased
- 2018-04-11 DK DK21211015.9T patent/DK4039675T3/da active
- 2018-04-11 RS RS20220154A patent/RS62933B1/sr unknown
- 2018-04-11 CN CN202310753648.5A patent/CN117510405A/zh active Pending
- 2018-04-11 MY MYPI2019006116A patent/MY199442A/en unknown
- 2018-04-11 PH PH1/2019/502363A patent/PH12019502363B1/en unknown
- 2018-04-11 EP EP21211015.9A patent/EP4039675B1/en active Active
-
2019
- 2019-10-16 ZA ZA2019/06811A patent/ZA201906811B/en unknown
- 2019-10-17 IL IL270005A patent/IL270005B/en unknown
- 2019-10-17 SA SA519410320A patent/SA519410320B1/ar unknown
- 2019-10-17 MX MX2022001310A patent/MX2022001310A/es unknown
- 2019-11-15 CO CONC2019/0012767A patent/CO2019012767A2/es unknown
-
2021
- 2021-12-09 IL IL288822A patent/IL288822B2/en unknown
-
2022
- 2022-03-01 CY CY20221100173T patent/CY1125150T1/el unknown
- 2022-07-18 AU AU2022206702A patent/AU2022206702B2/en active Active
- 2022-07-20 JP JP2022115300A patent/JP7331212B2/ja active Active
-
2023
- 2023-04-13 US US18/300,237 patent/US20230373922A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201708456D0 (en) | Senolytic compounds | |
| GB201704327D0 (en) | Compounds | |
| GB201715342D0 (en) | Compounds | |
| SI4039675T1 (sl) | Fenil-2-hidroksi-acetilamino-2-metil-fenilne spojine | |
| GB201704325D0 (en) | Compounds | |
| GB201716871D0 (en) | Compounds | |
| GB201713962D0 (en) | Compounds | |
| GB201717051D0 (en) | Compounds | |
| GB201707938D0 (en) | Compounds | |
| GB201707856D0 (en) | Compounds | |
| GB201706162D0 (en) | Compounds | |
| GB201702221D0 (en) | Compounds | |
| GB201716369D0 (en) | Compounds | |
| GB201715786D0 (en) | Compounds | |
| GB201720064D0 (en) | Compounds | |
| GB201716392D0 (en) | Compounds | |
| GB201707852D0 (en) | Compounds | |
| GB201703282D0 (en) | Compounds | |
| GB201721331D0 (en) | Compounds | |
| GB201721330D0 (en) | Compounds | |
| GB201721326D0 (en) | Compounds | |
| GB201720495D0 (en) | ß-lactone compounds | |
| GB201719261D0 (en) | Compounds | |
| GB201717718D0 (en) | Compounds | |
| GB201717050D0 (en) | Compounds |